Belite Bio (BLTE)
(Delayed Data from NSDQ)
$48.35 USD
+0.23 (0.48%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $48.10 -0.25 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BLTE 48.35 +0.23(0.48%)
Will BLTE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BLTE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLTE
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
BLTE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BLTE
Belite Bio to Present at the JonesHealthcare Seaside Summit
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
Buy Rating Affirmed for Belite Bio, ADR on Tinlarebant’s Promising Regulatory and Clinical Prospects
Belite Bio granted Sakigake Designation by Japan MHLW
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan